PDCD1 and melanoma: This particular study19 scrutinized the oral and gut microbiota of melanoma patients undergoing PD‐1 therapy and found that patients with a healthy gut microbiota had significantly better anti‐tumor immunity than the control group, indicating the important role of immune therapy and patient's gut microbiota characteristics in the treatment of melanoma.